載入...

The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

BACKGROUND: Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism behind this differential anti-tumour effect according to ER status, hypothesising i...

全面介紹

Na minha lista:
書目詳細資料
發表在:BMC Cancer
Main Authors: Wilson, Caroline, Ottewell, Penelope, Coleman, Robert E, Holen, Ingunn
格式: Artigo
語言:Inglês
出版: BioMed Central 2015
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4329195/
https://ncbi.nlm.nih.gov/pubmed/25884855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1066-7
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!